Table 2 Comparison of demographic, clinicopathological and radiological data between the 1st and 2nd decade
From: Assessment of clinico-epidemiological profile of Hepatocellular carcinoma in the last two decades
Parameter | Decade | Test of significance | |
|---|---|---|---|
1st decade (1999-2009) (n=257) | 2nd decade (2010-2019) (n=238) | P value | |
Age (years): | 57 (51-63) | 57 (53-63) | 0.496 |
Sex: | |||
Male: | 227 (87.6%) | 212 (89.1%) | |
Female: | 32 (12.4%) | 26 (10.9%) | 0.620 |
Residency: | |||
Rural | 161 (62.2%) | 179(75%) | 0.002 |
Urban | 98(37.8%) | 59(24.8%) | |
Smoking | 57(22%) | 55(23.1%) | 0.769 |
Positive HBsAg: | 3 (1.2%) | 9 (3.8%) | 0.057 |
Positive Anti-HCV: | 235 (90.7%) | 223 (93.7%) | 0.220 |
AFP level: | 268 (32-868.5) | 300 (22.5-1000) | 0.854 |
Presence of DM | 27 (10.4%) | 45 (19%) | 0.007 |
Presence of hypertension: | 14 (5.4%) | 23 (9.7%) | 0.071 |
Spleen | |||
Splenectomy | 9 (3.5%) | 2 (0.8%) | |
Normal-sized | 125 (48.3%) | 138 (58%) | |
Mild enlargement | 61 (23.6%) | 59 (24.8%) | 0.009 |
Moderate enlargement | 56 (21.6%) | 38 (16%) | |
Marked enlargement | 8 (3.1%) | 1 (0.4%) | |
Hepatic encephalopathy | |||
No | 216 (83.4%) | 159 (66.8%) | <0.0005 |
Mild | 31 (12%) | 47 (19.7%) | |
Moderate to severe | 12 (4.6%) | 32 (13.4%) | |
Liver size: | |||
Average | 129 (49.8%) | 139 (58.4%) | |
Mild enlargement | 69 (26.6%) | 65 (27.3%) | 0.055 |
Moderate enlargement | 34(13.1%) | 21 (8.8%) | |
Shrunken | 27 (10.4%) | 13 (5.5%) | |
Site of the tumor: | |||
Right lobe | 155 (67.4%) | 133 (59.9%) | |
Left lobe | 57 (24.8%) | 64 (28.8%) | 0.214 |
Both lobes | 18 (7.8%) | 25 (11.3%) | |
Number of focal lesions: | |||
One | 159(62.1%) | 145(61.2%) | |
Two | 21(8.2%) | 21(8.9%) | 0.001 |
Three | 43(16.8%) | 62(26.2%) | |
>three | 33(12.9%) | 9(3.8%) | |
Size of FHL (cm): | |||
Largest diameter | 5 (4-7) | 4.8 (3.9-8) | 0.3334 |
Portal vein thrombosis | 73 (28.2%) | 104 (43.7%) | <0.0005 |
Vascular invasion | 72 | 108 | <0.0005 |
LN metastasis | 74 | 110 | <0.0005 |
Distant metastasis | 111 | 88 | 0.008 |
Within MILAN criteria | 84 (32.4%) | 66 (27.7%) | 0.254 |
BCLC staging | |||
0 | 15 (5.8%) | 9 (3.7%) | 0.04 |
A | 69 (26.8%) | 57 (23.9%) | |
B | 8 (3.1%) | 8 (3.3%) | |
C | 79 (30.7%) | 122 (51.2%) | |
D | 48 (18.6%) | 82 (34.4%) | |